Reportable Segment Information (Tables)

6 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment for the three and six months ended March 31, 2024 and 2023.

	Three months ended						Six months ended
	March 31						March 31
(In millions - unaudited)	2024			2023			2024			2023
SALES
Life Sciences	$	222		$	240		$	422		$	447
Personal Care		169			167			298			305
Specialty Additives		157			161			279			304
Intermediates		40			51			73			105
Intersegment sales(a)		(13	)		(16	)		(24	)		(33	)
	$	575		$	603		$	1,048		$	1,128
OPERATING INCOME (LOSS)
Life Sciences	$	50		$	58		$	82		$	92
Personal Care		25			14			28			25
Specialty Additives		(18	)		15			(50	)		16
Intermediates		9			17			16			37
Unallocated and other		(45	)		(21	)		(72	)		(50	)
	$	21		$	83		$	4		$	120
DEPRECIATION EXPENSE
Life Sciences	$	11		$	10		$	20		$	20
Personal Care		9			10			17			20
Specialty Additives(b)		40			14			77			28
Intermediates		3			3			6			6
	$	63		$	37		$	120		$	74
AMORTIZATION EXPENSE
Life Sciences	$	5		$	7		$	12		$	14
Personal Care		11			11			22			22
Specialty Additives		4			5			6			9
Intermediates		—			—			—			1
	$	20		$	23		$	40		$	46
EBITDA(c)
Life Sciences	$	66		$	75		$	114		$	126
Personal Care		45			35			67			67
Specialty Additives		26			34			33			53
Intermediates		12			20			22			44
Unallocated and other		(45	)		(21	)		(72	)		(50	)
	$	104		$	143		$	164		$	240

	March 31		September 30
(In millions - unaudited)	2024		2023
TOTAL ASSETS
Life Sciences	$	1,915	$	1,904
Personal Care		982		1,004
Specialty Additives		1,526		1,580
Intermediates		135		136
Unallocated and other		1,390		1,315
	$	5,948	$	5,939

(a)Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.

(b)Depreciation includes accelerated depreciation of $27 million and $49 million for Specialty Additives for the three and six months ended March 31, 2024, respectively.

(c)Excludes loss from discontinued operations and other net periodic benefit loss. See the Statements of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.